Longevity company CEO Joe Betts-Lacroix reveals a disconnect between the FDA's stated goal of reducing animal models and its actual requirements. He states that in his company's interactions, the FDA has requested even more extensive animal studies, suggesting the move away from traditional preclinical testing is more rhetoric than reality.

The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

Legislation directing the FDA to update animal testing rules is not an outright ban. Instead, it aims to modernize regulations to incorporate newer methods like computational models and organoids, reflecting a slow convergence of technology, policy, and regulatory acceptance.

Non-human primate models are poor predictors of human immunogenicity. The industry has shifted to human-relevant ex vivo assays using whole blood or PBMCs. These tests can assess risks like complement activation upfront, enabling proactive protein engineering to improve a drug's safety profile.

The push away from animal models is a technical necessity, not just an ethical one. Advanced therapeutics like T-cell engagers and multispecific antibodies depend on human-specific biological pathways. These mechanisms are not accurately reproduced in animal models, rendering them ineffective for testing these new drug classes.

The FDA's proposal to use non-animal models for first-in-human trials is a long-term scientific shift. However, competitors like Australia and China achieve faster trial starts now by simply streamlining existing regulatory processes, making them more attractive for biotech companies in the short-term.

With support from the FDA and NIH, the industry is moving to standardize organoid systems. This shift transforms them from niche research tools into reliable, quality-controlled preclinical models that can be used for personalized medicine and to generate more predictable drug discovery data.

The NIH will no longer award funding to new grant proposals that rely exclusively on animal models. This policy forces a shift towards New Approach Methodologies (NAMs), such as organoids and organ-on-chips, serving as a major catalyst for innovation and adoption in the preclinical testing space.

The FDA is eliminating mandatory animal testing because it's often misleading—90% of drugs passing animal studies fail in humans. The agency is embracing modern alternatives like computational modeling and organ-on-a-chip technology to get faster, more accurate safety data.